Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey
Omer A. Syed, Rotem Petranker, Emily C. Fewster, Valentyn Sobolenko, Zeina Beidas, Muhammad Ishrat Husain, Stephanie Lake, Philippe Lucas
Journal of Psychoactive Drugs December 24, 2024 DOI: 10.1080/02791072.2024.2446445 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 6,379 |
| Population | Consumers of 11 different psychedelic substances from 85 countries |
| Keywords | Environmental considerations Natural sources Psychedelics Synthetic substances Environmental conservation Consumer preferences Drug sustainability |
| Citations | 3 |
| Key findings | Consumers prefer natural over synthetic sources for psilocybin, DMT, and mescaline, but most would switch to synthetic alternatives to lessen environmental impacts from overharvesting. |
Abstract
Although several studies have well described the characteristics of people who use psychedelics alongside their motivations and beliefs, little research has examined the preferences surrounding the source of psychedelic substances. In an anonymous online survey, we collected data from 6,379 consumers of 11 different psychedelic substances from 85 different countries, exploring their preferences and perceptions on natural and synthetic psychedelics. There was a strong preference of natural sources over synthetic alternatives for psilocybin (75%), DMT (56%), and mescaline (56%). Moreover, 50.8% of respondents believed that the source impacts the psychedelic's psychological and physiological effects, while 34.4% of respondents had a neutral stance on the topic. Despite the preference for natural sources, 67.7% of respondents agreed to switch to using synthetic alternatives to psychedelic substances if it would lessen the environmental impacts caused by the overharvesting of natural sources. This study presents novel insights into consumer preferences on the source of popular psychedelic substances. This international survey is limited to respondents primarily belonging to anglophone regions of the world.
Citations in the library
Cited by 4
- Real-World Therapeutic Use of Ketamine in Clinical and Non-Clinical Settings: A Cross-Sectional Survey Journal of Psychoactive Drugs September 23, 2026
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development Biomolecules July 3, 2026
- Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States Journal of Psychoactive Drugs June 19, 2026
- Of shrub, cactus, vine and toad: psychedelic species of conservation concern Frontiers in Conservation Science September 29, 2025
Cites 33
- Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Acta Psychiatrica Scandinavica October 30, 2020
- A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology April 13, 2019
- The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro Scientific Reports July 7, 2017
- Psychedelic Drug Legislative Reform and Legalization in the US JAMA Psychiatry December 7, 2022
- Psychedelic microdosing benefits and challenges: an empirical codebook Harm Reduction Journal July 9, 2019
and 28 more in the library